Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease
- 7 November 2006
- journal article
- review article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 48 (9) , A24-A32
- https://doi.org/10.1016/j.jacc.2006.04.097
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- Peroxisome proliferator‐activated receptor δ as a molecular target to regulate lung cancer cell growthFEBS Letters, 2005
- PPARγ and atherosclerosisCurrent Medical Research and Opinion, 2005
- Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statinThe American Journal of Cardiology, 2005
- Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetesAmerican Heart Journal, 2004
- Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitusThe American Journal of Cardiology, 2004
- Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning studyAmerican Heart Journal, 2003
- Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery DiseaseCirculation, 2003
- Lipid-lowering drugs and homocysteineThe Lancet, 1999
- Obesity Associated with a Mutation in a Genetic Regulator of Adipocyte DifferentiationNew England Journal of Medicine, 1998
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987